Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ARG1 | P05089 | 4/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17756064 | 1.00 | SLC1A2 (0.58) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL2177343 | 0.90 | MEN1 (0.61) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL17756096 | 0.90 | MEN1 (0.61) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL630081 | 0.89 | SLC1A2 (0.49) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL30850131 | 0.80 | SLC1A2 (0.64) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL10430282 | 0.80 | SLC1A2 (0.64) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL24023397 | 0.78 | MAPT (0.39) | SLC1A2MEN1KMT2A | |
| SCHEMBL9507401 | 0.77 | SLC1A2 (0.38) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL27190337 | 0.77 | MEN1 (0.61) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL9511045 | 0.77 | MEN1 (0.61) | SLC1A2MEN1BLMKMT2AARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250167-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | Chlorion Pharma, Inc. (CA) | 2010-11-17 | — | — | EP | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
| US-4833152-A | Anti-hypertensive agents | UNIVERSITY OF MIAMI (US) | 1989-05-23 | — | — | US | disclosed |
| US-4745124-A | THIO/ESTER PEPTIDES | UNIVERSITY OF MIAMI (US) | 1988-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | SLC1A2 1794/4885MEN1 4697/4885BLM 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.